Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Top Page
NRX Pharmaceuticals
(NASDAQ:NRXP)
44Neutral
Positive Factors
Earnings Potential
NRx Pharmaceuticals is targeting achievement of $100M in revenue in 2025 and could become profitable with just $38M in revenue.
Market Opportunity
According to market research, the anti-suicide market is projected to reach $5B by 2026, indicating a significant opportunity for NRx to capture market share with NRX-100.
Strategic Partnerships
NRX-100 has attracted interest from a commercial-stage pharmaceutical company, providing NRx with an opportunity to consider non-binding terms for an out-licensing and distribution agreement potentially worth up to $300M.
Negative Factors
Development Stage
NRx Pharmaceuticals is a developmental-stage biotechnology company working broadly in suicidal ideation and behavior, a large area of unmet need that has seen essentially no improvement in treatment outcomes in 50 years.
Market Competition
There is no medicine approved to treat patients with bipolar depression suffering suicidal ideation, presenting a large market potential.
NRX Pharmaceuticals (NRXP) vs. S&P 500 (SPY)
Market Cap
$34.68M
Dividend YieldN/A
Average Volume (3M)186.39K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue GrowthN/A
EPS Growth41.01%
CountryUS
Employees2
SectorHealthcare
Sector Strength64
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.71
Shares Outstanding16,915,648
10 Day Avg. Volume163,781
30 Day Avg. Volume186,386
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.50Price Target Upside834.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NRX Pharmaceuticals Business Overview & Revenue Model
Company DescriptionNRX Pharmaceuticals (NRXP) is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of central nervous system disorders and other critical health conditions. The company operates in the healthcare sector with a particular emphasis on drug development for serious mental illnesses, respiratory diseases, and other critical care indications. Its core products include investigational drugs designed to offer new treatment options for patients with severe mental health disorders and life-threatening pulmonary diseases.
How the Company Makes MoneyNRX Pharmaceuticals makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue streams include partnerships with other pharmaceutical companies for drug development and distribution, as well as potential sales from its proprietary drugs once they receive regulatory approval. Additionally, NRX Pharmaceuticals may engage in licensing agreements, where they receive upfront payments, milestone payments, and royalties based on the sales performance of their licensed products. The company's earnings are also influenced by its ability to secure funding through investments, grants, or collaborations geared towards advancing its research and development efforts.
NRX Pharmaceuticals Financial Statement Overview
Summary
NRX Pharmaceuticals is in a challenging financial position with ongoing net losses, negative equity, and reliance on external financing. This is typical for biotechnology firms in early stages, but the company must address revenue generation and manage its cash flow effectively to improve financial health.Income Statement
NRX Pharmaceuticals shows consistent net losses and zero revenue over the years, leading to negative EBIT and EBITDA margins. There is no revenue growth, which is typical for early-stage biotech firms focusing on R&D and product development. The company faces challenges in transitioning from R&D to revenue generation.10
Very Negative
Balance Sheet
The balance sheet reveals negative stockholders' equity and high liabilities compared to assets, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, suggesting high financial risk. However, the absence of debt in the latest report is a slight positive aspect.20
Very Negative
Cash Flow
Operating cash flow remains negative, reflecting ongoing cash burn without incoming revenue. The free cash flow is also negative, indicating the company relies on financing activities for liquidity. This cash flow scenario is common in biotech companies at the research stage.15
Very Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -5.00K | -4.00K | -2.00K | -907.41K | EBIT |
| -18.50M | -27.59M | -44.40M | -115.80M | -51.39M | EBITDA |
| -18.50M | -30.02M | -39.75M | -93.04M | -51.72M | Net Income Common Stockholders |
| -25.13M | -30.15M | -35.23M | -71.72M | -12.35M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.44M | 4.59M | 20.05M | 27.61M | 1.86M | Total Assets |
| 3.65M | 7.32M | 25.82M | 32.73M | 2.94M | Total Debt |
| 6.58M | 9.16M | 10.53M | 518.00K | 797.00K | Net Debt |
| 5.13M | 4.57M | -9.53M | -27.09M | -1.06M | Total Liabilities |
| 26.87M | 19.05M | 18.41M | 11.92M | 46.71M | Stockholders Equity |
| -23.22M | -11.73M | 7.41M | 20.81M | -43.77M |
| Cash Flow | Free Cash Flow | |||
| -10.64M | -21.66M | -39.77M | -37.71M | -2.27M | Operating Cash Flow |
| -10.64M | -21.66M | -39.76M | -37.70M | -2.27M | Investing Cash Flow |
| 0.00 | -3.00K | -10.00K | -7.00K | -2.00K | Financing Cash Flow |
| 7.49M | 6.20M | 32.21M | 63.46M | 3.25M |
NRX Pharmaceuticals Technical Analysis
Negative
1.98
Price Trends
2.18
Negative
2.32
Negative
2.02
Negative
Market Momentum
-0.08
Negative
44.98
Neutral
54.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXP, the sentiment is Negative. The current price of 1.98 is above the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.18, and below the 200-day MA of 2.02, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 44.98 is Neutral, neither overbought nor oversold. The STOCH value of 54.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRXP.
NRX Pharmaceuticals Risk Analysis
NRX Pharmaceuticals disclosed 100 risk factors in its most recent earnings report. NRX Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NRX Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
45 Neutral | $34.72M | ― | -1192.69% | ― | ― | 61.43% | |
44 Neutral | $34.68M | ― | 108.28% | ― | ― | 41.01% | |
31 Underperform | $39.49M | ― | 1063.61% | ― | 1404.02% | 59.49% | |
28 Underperform | $35.43M | ― | -916.17% | ― | ― | 45.15% |
* Healthcare Sector Average
Performance Comparison
NRXP
NRX Pharmaceuticals
1.98
-1.16
-36.94%
ATRA
Atara Biotherapeutics
6.90
-10.60
-60.57%
RVPH
Reviva Pharmaceuticals Holdings
0.86
-2.12
-71.14%
RNXT
RenovoRx
0.98
-0.23
-19.01%
NRX Pharmaceuticals Earnings Call Summary
Earnings Call Date: Mar 17, 2025 | % Change Since: -15.74% | Next Earnings Date: May 20, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in drug development, potential strategic partnerships, and financial improvements, particularly with the expansion of HOPE Therapeutics. However, challenges remain due to the unsupportive capital market environment, low cash reserves, and regulatory complexities in clinic acquisitions. Despite these challenges, the positive developments and strategic initiatives outweigh the negatives.Highlights
Progress in Drug Development
NRx has made significant progress in drug development, including initiating the filing of a New Drug Application (NDA) for NRX-100, their preservative-free intravenous ketamine, and preparing an accelerated NDA filing for NRX-101. They have also developed a patentable version of pH-neutral ketamine, HTX-100, expected to begin human bioequivalence studies this year.
Potential Strategic Partnership
NRx received a strategic term sheet to acquire NRX-100 for more than $300 million in total milestones and a double-digit royalty, validating their drug development approach.
Financial Improvements
NRx Pharmaceuticals reduced its loss from operations by approximately $9.3 million, a 33.5% decrease, primarily driven by a reduction in research and development expenses.
HOPE Therapeutics Expansion
HOPE Therapeutics has signed nonbinding letters of intent to acquire three profitable interventional psychiatry clinics, with plans to acquire more in Florida and other locations. They aim to have 15 to 20 facilities by year-end 2025.
Financing and Capitalization
The company closed its third tranche of funding from Anson Funds, bringing the total financing to nearly $20 million, and anticipates that HOPE Clinics will be financed through non-dilutive means.
Lowlights
Challenges in Capital Markets
The company is operating in a capital market environment that has been less supportive of pre-revenue biotechnology companies, posing challenges for fundraising and expansion.
Cash Position
As of December 31, 2024, NRx had approximately $1.4 million in cash and cash equivalents, which is relatively low despite recent financings.
Regulatory and Acquisition Complexities
The acquisition of medical treatment facilities involves navigating complex legal and regulatory requirements, which could delay expansion plans.
Company Guidance
During the NRx Pharmaceuticals 4Q and Full Year 2024 earnings call, the company provided detailed guidance on their strategic path forward. Over the past five months, they raised new capital, retired toxic debt, and began transitioning from a research-focused entity to a revenue-generating healthcare company. They announced the initiation of a New Drug Application (NDA) for NRX-100, a preservative-free intravenous ketamine, supported by data indicating over two years of room temperature shelf stability, with manufacturing capacity exceeding 1 million doses per month. NRx has received a strategic term sheet to acquire this product for over $300 million in total milestones and a double-digit royalty. Additionally, they are preparing an accelerated NDA filing for NRX-101, a combination of D-cycloserine and lurasidone, targeting a 2025 PDUFA date. NRx also launched HOPE Therapeutics, aimed at delivering clinical care through interventional psychiatry clinics, anticipating profitability by the end of 2025. Financially, the company reduced its operational loss by 33.5% to $18.5 million, with significant decreases in research and development expenses. Recent financings raised nearly $20 million, expected to sustain operations through 2025.NRX Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
NRX Pharmaceuticals Reports 2024 Financial Results and Strategy
Positive
Mar 21, 2025
NRx Pharmaceuticals announced its financial results for the fourth quarter and full year 2024, highlighting significant advancements in its drug development and corporate strategy. The company initiated the filing of a New Drug Application for NRX-100 for suicidal depression and plans to file for NRX-101 for bipolar depression. Additionally, NRx Pharmaceuticals is negotiating licensing agreements for NRX-100 and pursuing acquisitions to establish a national network of interventional psychiatry centers. These efforts aim to strengthen the company’s position in the mental health treatment market and potentially increase its profitability by the end of 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.